Aug 5 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O reported a quarterly profit on Wednesday that rose more than four times, helped by a $228 million gain and on higher sales of its blockbuster eczema treatment Dupixent.
Net income rose to $897.3 million, or $7.61 per share, in the second quarter ended June 30, from $193.1 million, or $1.68 per share, a year earlier.
Revenue rose to $1.95 billion from $1.58 billion.
(Reporting by Dania Nadeem and Manojna Maddipatla in Bengaluru; Editing by Shounak Dasgupta)
((Dania.Nadeem@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6182 3463))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.